BiVictriX identifies lead for BVX001 programme

RNS Number : 8267I

BiVictriX Therapeutics PLC

07 December 2022

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company" or the "Group")

BiVictriX identifies development lead for BVX001 programme

Lead identified for the BVX001 programme which demonstrates encouraging potency and enhanced cancer selectivity

Lead will now be progressed to in vivo studies to obtain readouts on preclinical efficacy and safety

Alderley Park, 7 December 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces that it has identified a development lead for its BVX001 programme (the "Lead").

The Lead was developed using BiVictriX's proprietary Bi-Cygni® approach, which aims to generate the next-generation of Antibody Drug Conjugates ("ADCs") with superior cancer selectivity. The Lead was selected based on promising in vitro potency and cancer cell selectivity data, together with encouraging data reported from a panel of ex-vivo safety assays using healthy human cells.

The Lead, together with backup candidates, will now be taken forward into a panel of in vivo models. These will include models of Acute Myeloid Leukaemia to investigate the optimum dose of the molecule.  In addition, the Lead will be assessed in safety models providing indicative safety data for the programme. Results from these experiments, in addition to the data already obtained, will support manufacturing preparations and guide future clinical trials.

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, commented: "We are delighted to be able to announce that we have identified a lead compound for our BVX001 programme, in line with what we set out to do earlier this year. This marks a significant step forward towards progressing this programme to the clinic, where we hope to deliver key outcomes for patients who currently have limited options. This announcement also comes at a time when interest in the ADC sector is on the rise with over 12 deals/partnerships announced this year alone. I would like to thank the team at BiVictriX for all their hard work in achieving this fundamental milestone. "

For more information, please contact:

BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman	Email: [e-mail]
SP Angel Corporate Finance LLP (NOMAD and Broker)	Tel: [phone]
David Hignell, Kasia Brzozowska (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking)
Panmure Gordon  (UK) Limited (Joint Broker) Rupert Dearden, Freddy Crossley, Emma Earl Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott, Namrata Taak, Genevieve Wilson, Alex Gunter	Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related harmful side effects.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target cancer-specific antigen pairs, or "twin antigens fingerprints", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting, where it offers the opportunity to be a game-changing approach to cancer care.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens fingerprints" across a broad range of cancer indications. The Company is using these novel twin antigens to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com .

 

END

 

 

MSCDGBDDIGGDGDL